Previously differentiated medial vascular smooth muscle cells contribute to neointima formation following vascular injury

Abstract

Background

Vascular smooth muscle cells (VSMCs) are the major contractile components of the vascular system. They are critically important for regulating blood pressure and flow throughout the vascular system. Unlike skeletal and cardiac muscle cells, VSMCs are remarkably plastic and modulate their phenotype in response to extracellular cues during the development and progression of a variety of diseases including atherosclerosis, hypertension, stenosis following injury and restenosis following vascular interventions. Cardiovascular disease is the leading cause of death among the US population, yet despite intense research efforts a number of basic questions regarding the etiology of cardiovascular disease remain elusive. Classically these diseases are described as being associated with dedifferentiated VSMCs that have decreased expression of proteins required for the normal contractile function, increased expression of extracellular matrix proteins and increased cell proliferation [1]. These proliferating dedifferentiated VSMCs are a major component of neointimal lesions and atherosclerotic plaques. Neointimal VSMCs have been proposed to arise from several sources, including blood and bone marrow derived precursor cells, dedifferentiated medial VSMCs, resident progenitor cells and adventitial fibroblasts. However, recent definitive studies showed a relatively minor contribution of blood and bone marrow derived cells to the neointima or atherosclerotic plaque VSMC population [2–5]. The most widely accepted paradigm that neointimal VSMCs arise from the dedifferentiation and migration of medial VSMCs has been recently challenged [6]. This finding has stimulated much controversy in the field [7] and has prompted us to further investigate the origin of these cells. Using a genetic fate mapping approach with tamoxifen regulated smooth muscle-specific cre recombinase and a dual color cre-dependent reporter gene we unequivocally show that the neointimal SMCs that arise following carotid artery ligation are largely derived from the previously differentiated medial VSMCs.

Methods

Transgenic mice and carotid ligation

All animal procedures were performed using procedures approved by the Indiana University School of Medicine Institutional Animal Care and Use committee under protocol number 10310. Smooth muscle myosin heavy chain (Myh11) creER(T2)^-/+ mice [8] (on a C57BL6 background) and smooth muscle α-actin (Acta2) creER(T2)^-/+ mice [9] were crossed with mTmG reporter mice (Jackson strain: B6.129(Cg)-Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/J) (Figure 1). creER(T2) transgenes were used under agreement from the Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC). Double heterozygous transgenic mice were used for all experiments unless indicated otherwise. At 5-6 weeks of age mice were treated with Tamoxifen (1 mg/mouse IP) or corn oil control, once a day for 5 days. 2 weeks following the last treatment the left carotid artery was ligated as described previously [10]. Prior to surgery mice were anesthetized with intraperitoneal injection of ketamine/xylazine (0.088 mg/gm, 0.012 mg/gm). Following surgery mice were given a single subcutaneous injection of carprofen analgesic (0.5 mg). At various times following ligation mice were sacrificed under anesthesia (intraperitoneal injection of ketamine/xylazine (0.088 mg/gm, 0.012 mg/gm) and the injured and control contralateral carotid arteries were harvested and fixed in 4% paraformaldehyde for 2 hours on ice. Following fixation, vessels were washed in phosphate buffered saline for 3× 5 minutes and then frozen in OCT tissue freezing media (Tissue-Tech) on a bed of dry ice/2-methylbutane. 8 μm cryosections were cut and stored at -80°.

Figure 1   ( Jump back to reading ◀ )

Figure 1 caption

Schematic representation of the mTmG reporter strain. The mTmG reporter mice (Jackson strain: B6.129 (Cg)-Gt(ROSA)26Sor/J ) contain a single copy of the transgene integrated into the ROSA 26 locus. The transgene cassette is comprised of a chimeric CMV, β-actin promoter driving the expression of a floxed membrane localized Tomato tandem dimer. Following cre-mediated excision the mTomato transgene is removed such that the CAG promoter now drives expression of membrane localized EGFP. The reporter mice were crossed with transgenic mice that express a tamoxifen regulated cre recombinase directed to smooth muscle cells by either the promoter or the promoter. Double heterozygous transgenic mice were used for all experiments.

Results

Results of a recent study suggest that neointimal cells that form following vascular injury are derived from a stem cell population resident within the vascular wall rather than from previously differentiated VSMCs [6]. In that study fate mapping experiments were performed in which differentiated VSMCs were tagged using a cre-dependent EGFP reporter strain crossed with transgenic mice expressing cre recombinase exclusively in smooth muscle cells (B6.Cg-Tg(Myh11-cre,-EGFP)2Mik/J) [12]. The conclusion that previously differentiated VSMCs do not contribute to neointima formation was thus, based largely on the inability to detect EGFP-positive cells in the neointima in these mice. As there are many factors that can contribute to a negative result in these experiments, including the reported silencing of the ROSA 26 promoter that was used to drive EGFP expression in neointimal cells [13], we reevaluated these findings using an alternative fate mapping strategy. We utilized a dual color reporter transgenic mouse line (mTmG: B6.129(Cg)-Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/J) in which all cells express a membrane localized mTomato tandem dimer in the absence of cre recombinase activity. Following cre-mediated excision of the mTomato cassette, cells express membrane localized EGFP [14] (Figure 1). In this reporter mouse line, both mTomato and mEGFP are driven by the same CMV/β-actin (CAG) promoter that has been shown to be active in neointimal cells [13]. This dual color reporter strain obviates the need to interpret negative data, as all neointimal cells should be either red or green depending on whether they express mTomato of mEGFP, respectively. To specifically identify differentiated VSMCs we crossed the mTmG mice with mice expressing a tamoxifen regulated cre recombinase directed by the smooth muscle-specific Myh11 [8] or Acta2 [9] promoters. The ability to temporally control cre recombinase activity also permitted us to distinguish previously differentiated VSMCs from newly differentiated VSMCs. Mice were treated with tamoxifen to activate the cre recombinase 2 weeks prior to vascular injury. As tamoxifen is rapidly metabolized in mice, at the time of surgical injury and subsequently, any cre recombinase expressed in VSMCs will be inactive and thus unable to switch cells from mTomato positive to mEGFP positive. Thus only VSMCs that were differentiated during the period of tamoxifen treatment, prior to injury will be mEGFP positive. As cre-mediated recombination results in a permanent heritable change in a cell’s genome these cells and any of their progeny will remain mEGFP positive even if they dedifferentiate and loose expression of cre or Myh11 or Acta2.

In Myh11 creER(T2)^-/+ mTmG^-/+ double transgenic mice [8] and Acta2 creER(T2)^-/+ mTmG^-/+ [9] double transgenic mice (Figure 1) treatment with tamoxifen results in cre mediated recombination and thus subsequent expression of mEGFP specifically in vascular and visceral smooth muscle cells (Figures 2 and 3). No mEGFP expression was observed in endothelial cells, adventitial cells, cardiac or skeletal muscle cells (Figures 2 and 3). 7 days following injury in Myh11 creER(T2)^-/+ mTmG^-/+ double transgenic mice we observed a significant decrease in expression of the endogenous Myh11 gene within the medial layer of carotid arteries as evidenced by decreased smooth muscle myosin isoform, SM2, immunostaining (Figure 4). This is consistent with the previously reported dedifferentiation of medial VSMCs that follows vascular injury [15]. Despite the observed decreased Myh11 expression, the medial mEGFP expression was similar in control and injured vessels 7 days following injury, suggesting that the CAG promoter, which drives mEGFP expression, is not affected by injury (Figure 4). At this time point we did not observe any significant neointima formation in any of the three mice examined. In contrast, 14 days following ligation we observed small amounts of neointima formation in 3 out of 4 mice examined (Figure 5). In these mice, mEGFP positive cells can be readily seen within the neointima suggesting that these cells are derived from previously differentiated (Myh11 positive) medial VSMCs. Immunostaining with antibodies to CD31 demonstrate that there are also a number of CD31 positive, mTomato positive endothelial like cells within the neointima (Figure 6). We also observed some CD68 positive macrophage/monocytes in the neointima of some mice although these appeared less abundant than the CD31 positive cells (Figure 7).

Figure 2   ( Jump back to reading ◀ )

Figure 3   ( Jump back to reading ◀ )

Figure 4   ( Jump back to reading ◀ )

Figure 5   ( Jump back to reading ◀ )

Figure 6   ( Jump back to reading ◀ )

Figure 7   ( Jump back to reading ◀ )

To better quantitate the contribution of mEGFP positive cells to neointima formation we examined more mature lesions that formed 28 days following ligation. In most Myh11 creER(T2)^-/+ mTmG^-/+ double transgenic mice 28 days following carotid ligation the majority of neointimal cells also expressed mEGFP (Figure 8, Table 1). However, in one mouse the neointima was comprised of only 42% of mEGFP positive cells (Mouse#6 in Table 1, Figure 9B, C). In this mouse the lesion was very unusual in that it extended out in a bulb like structure from one side of the vessel wall (Figure 9B). Many of the mTomato positive cells in this lesion also stained positive for either CD31 or CD68 suggesting a large number of endothelial cells and macrophages or monocytes in the lesion (Figure 9B, C). In contrast, no CD68 positive cells were detected in most mature lesions and only a few scattered endothelial cells were seen within these lesions, although they could be readily seen lining the residual vessel lumens (Figure 9A). In another mouse, not shown in Table 1, we did not observe any concentric neointima formation 28 days following injury. In contrast, in this mouse there was an mEGFP negative cluster of CD31 positive cells that covered approximately 50% of the vessel lumen. As this structure occurred close to the point of ligation (<100 μm away), was very focal only extending for about 300 μm, was atypical in shape and comprised of CD31 positive cells we speculate that it was an organized thrombus rather than a true neointimal lesion. This mouse was thus excluded from our analyses. In control mice, given corn oil instead of tamoxifen, almost all cells remained mTomato positive and mEGFP negative (Figure 8, lower right panel). One mEGFP positive cell can be seen in the media of the corn oil treated vessel (green/yellow cell indicated by arrow head). This cell likely represents one in which the creER(T2) protein has moved to the nucleus in the absence of the tamoxifen ligand. As this cell also seems to express some mTomato (accounting for its yellow color) it is likely that the recombination event occurred within a few days of tissue harvesting such that the residual mTomato protein has not had time to completely turn over and disappear from the cell.

Figure 8   ( Jump back to reading ◀ )

Consistent with data obtained from the Myh11 cre mice, when previously differentiated VSMCs were tagged with the use of Acta2 cre the majority of the neointimal cells were mEGFP positive (range 63-94%; mean of 81 ± 12%; Figure 10, Table 1). Although the data presented suggest that many neointimal cells are derived from previously differentiated (Myh11 or Acta2 positive) medial VSMCs it is possible that these cells may be mobilized from distant sites rather than being derived from locally resident medial VSMCs. To evaluate the existence of a population of mobile mEGFP positive cells we performed a fluorescence activated cell sorting (FACS) analysis of blood obtained from tamoxifen treated Myh11 creER(T2)^-/+ mTmG^-/+ double transgenic mice, 7,14 and 28 days following injury (Figure 11). This analysis failed to detect the presence of any significant numbers of mEGFP positive circulating cells suggesting that the mEGFP positive neointimal cells are most likely locally derived.

Figure 10   ( Jump back to reading ◀ )

Figure 11   ( Jump back to reading ◀ )

Discussion

Results from the current studies support the widely accepted paradigm that following vascular injury medial VSMCs dedifferentiate and migrate into the lumen of vessels forming a neointima. As we utilized a tamoxifen regulated cre recombinase and waited 2 weeks after tamoxifen treatment before performing carotid ligation, given the 12 hour half life of tamoxifen in serum, it is highly unlikely that mEGFP positive cells seen following injury are derived from newly differentiated cells. Moreover, the use of a dual color reporter system avoided any artifacts that may arise due to promoter or reporter silencing as all cells should be either mTomato or mEGFP positive thus no conclusions need to be drawn that are based on negative staining data. Our data also suggest that unlike the ROSA-LACz reporter gene [13] the CMV enhancer/chicken beta-actin core promoter (CAG) driven mTmG reporter gene is not down-regulated in neointimal SMCs (compare the mEGFP intensity of control and injured vessels in Figures 3,8 and 10). The use of the mTmG reporter strain has the additional advantage that the reporter proteins are membrane localized and thus better retained during sample processing. Moreover, this is a single copy, targeted transgene, hence, it is also not subject to complications that may arise from partial recombination of multicopy transgenes, such that in each cell’s nucleus either the mTomato gene is present or it is excised. Cells will thus express either mTomato or mEGFP. Anecdotally we have noted, that the mTomato protein is relatively stable such that after tamoxifen treatment smooth muscle cells can have detectable expression of both mTomato and mEGFP for 3-4 days before the mTomato protein is turned over and degraded. We speculate that one or more of these advantages of the mTmG reporter system and tamoxifen regulated cre transgenes used in our study may explain why we were able to detect mEGFP positive neointimal cells whereas they were not detected in a previous study [6].

Our data are consistent with and extend previous fate mapping studies using a cre-dependent LacZ reporter [5]. In this study a cre-dependent ROSA-LacZ reporter was used together with Myh11-creER(T2) transgenic mice to show that following femoral artery wire injury the neointima that formed contained LacZ positive cells [5]. Together these studies suggest that in both the small concentric lesions that form following femoral wire injury and the more complex large lesions that form following carotid ligation, neointimal cells arise from differentiated medial VSMCs. Our rigorous quantitative analysis using 1 μm optical sections to obtain Z-stack series through the entire thickness of each 8 μm section, revealed some heterogeneity between mice, with mEGFP positive cells comprising 42-94% of total neointimal cells (Table 1). Although most mice have between 70-90% mEGFP positive neointimal cells, this may perhaps account for some of confusion in the literature related to the contribution of different cell types to the neointima. Despite this variability, the data indicate that, on average, the majority (~80%) of neointimal cells arise from the previously differentiated medial SMCs. This number would be consistent with previous studies that showed that about 20% of neointimal cells are derived from blood borne cells [4]. In further support of the contribution of blood or endothelial derived cells to the neointima some of the mTomato positive, mEGFP negative neointimal cells observed in our study, stained positive for endothelial and monocyte markers (CD31 and CD68, respectively; Figures 6,7 and 9). It is perhaps a little surprising that in some lesions there were more CD31 positive endothelial cells within the lesions than CD68 positive monocytes/macrophages. Some of these CD31 positive endothelial cells may be present in new vessels that are growing within the neointima (e.g. Figure 6, lower panels) and some may be miscounted lumen endothelial cells in which the plane of the section has obscured a luminal invagination. We also speculate that the proliferating neointimal smooth muscle cells may trap endothelial cells within the lesion as they extend out into the vessel lumen.

Conclusions

Although our studies do not rule out the possibility that under appropriate, in vitro, culture conditions the expansion of a progenitor cell population may be favored, the current studies provide compelling evidence that, in vivo, the majority of neointimal cells that arise following carotid ligation are derived from differentiated medial VSMCs. The lack of detectable mEGFP positive cells circulating in the blood, further suggests that the neointimal cells likely arise from the dedifferentiation and migration of locally derived medial VSMCs.

Acknowledgements

This research was supported by research support funds from IUPUI.

We would like to thank Dr. Joseph Miano, Dr. Richard Karas and Dr. Matthew Distasi for providing the Myh11 creER(T2), Acta2 creER(T2) and CAG-EGFP mice, respectively. We thank Drs. Daniel Metzger and Pierre Chambon for generating the creER(T2) construct and Acta2 creER(T2) mice and we would also like to thank Dr. Julian Albarran Juarez for sharing his unpublished data and for advice on the study.